<DOC>
	<DOCNO>NCT02744092</DOCNO>
	<brief_summary>The overarch objective study determine effectiveness LMWH/ warfarin vs. DOAC anticoagulation prevent recurrent VTE cancer patient . The intervention strategy Direct Oral AntiCoagulants ( DOAC ) therapy edoxaban , apixaban , rivaroxaban , dabigatran . The comparator low molecular weight heparin ( LMWH ) alone warfarin . The information gain empower cancer patient physician make informed choice anticoagulation strategy manage VTE .</brief_summary>
	<brief_title>Direct Oral Anticoagulants ( DOACs ) Versus LMWH +/- Warfarin VTE Cancer</brief_title>
	<detailed_description>Venous blood clot affect nearly million Americans year . Venous clot leg call deep venous thrombosis ( DVT ) dangerous travel lung cause blockages know pulmonary embolus ( PE ) . DVT PE call venous thromboemboli ( VTE ) . Cancer risk factor nearly 200,000 VTEs cancer patient year . The purpose VTE treatment prevent initial clot spread prevent new clot form . This accomplish thin blood , anticoagulation . Without anticoagulation , VTEs recur often fatal . Recently , FDA approve 4 new Direct Oral AntiCoagulants ( DOACs ) prevent VTE recurrence . Few cancer patient include efficacy trial , practice guideline fall silent whether switch DOAC therapy advisable . To fill knowledge gap , Alliance Foundation Trials LLC , research network academic community practice across US , conduct pragmatic randomized effectiveness trial . The overarch objective study determine effectiveness LMWH/ warfarin vs. DOAC anticoagulation prevent recurrent VTE cancer patient . The investigator conduct trial 940 cancer patient follow 6 month . The intervention strategy DOAC therapy edoxaban , apixaban , rivaroxaban , dabigatran . The comparator LMWH alone warfarin . Within arm , patient choose agent prefer base side effect , drug interaction , practical issue co-pays . The trial compare two strategy term treatment : 1 ) benefit base VTE recurrence ; 2 ) harm base bleed rate ; 3 ) burden base patient ' report experience ; 4 ) mortality rate . The investigator hypothesize benefit , harm burden DOAC treatment non-inferior , good , usual care LMWH/ warfarin among cancer patient . The information gain empower cancer patient physician make informed choice anticoagulation strategy manage VTE .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Diagnosis advance solid tumor cancer , lymphoma , myeloma ( time restriction limitation ) OR diagnosis early stage solid tumor cancer , lymphoma , myeloma &lt; = 12 month prior study enrollment Diagnosis VTE &lt; = 30 day prior study enrollment potential benefit anticoagulation therapy prevent recurrence VTE felt treat physician exceed potential harm Any anticoagulation drug/strategy may use treat index VTE ; protocol treatment begin &lt; = 30days index VTE diagnosis date Treating physician intend put participant anticoagulation therapy least three month . Age &gt; = 21 year Platelet count &gt; = 50,000/mm^3 ( &lt; = 7 day prior enrollment ) CrCl ( Creatinine Clearance ) &gt; = 15 ml/min ( &lt; = 7 day prior enrollment ) Diagnosis acute leukemia Has ever receive scheduled receive Allogeneic Hematopoietic Stem Cell Transplantation ( alloHSCT ) Patients ever receive Autologous Hematopoietic Stem Cell Transplantation ( autoHSCT ) ARE eligible . Patients schedule receive Autologous Hematopoietic Stem Cell Transplantation ( autoHSCT ) NOT eligible Ongoing , clinically significant bleeding ( CTCAE grade 3 4 ) Ongoing therapy Pgp inhibitor ( e.g. , nelfinavir , indinavir , saquinavirprotease inhibitor HIV ) drug interact factor Xa inhibitor Therapy azole antifungal ( e.g. , itraconazole , ketaconazole , voriconazole ) time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rivaroxaban ( Xarelto )</keyword>
	<keyword>Apixaban ( Eliquis )</keyword>
	<keyword>Edoxaban ( Savaysa )</keyword>
	<keyword>Dabigatran ( Pradaxa )</keyword>
	<keyword>Warfarin ( Coumadin )</keyword>
	<keyword>Low molecular weight heparin ( LMWH )</keyword>
</DOC>